OBJECTIVE:Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed medications for geriatric depression. The association of late-life depression and cognitive impairment has been well documented. However, there have been few placebo-controlled trials examining the impact of SSRIs on cognitive functioning. DESIGN: Prepost neuropsychological (NP) data collected as part of an 8-week, double-blind, placebo-controlled trial of citalopram in depressed patients aged 75 years and older were used to examine change in cognitive functioning. SETTING: University-affiliated outpatient psychiatry clinics. PARTICIPANTS: One hundred seventy-four community-dwelling men and women aged 75 years or older with nonpsychotic unipolar depression. MEASUREMENTS: NP assessments included mental status (Mini-Mental State Examination), psychomotor speed (Wechsler Adult Intelligence Scale-III Digit Symbol Subtest), reaction time (Choice Reaction Time), visual-spatial skill (Judgment of Line Orientation), executive functioning (Stroop Color/Word Test), and memory (Buschke Selective Reminding Test). RESULTS: Differences in the pattern of change by treatment group depended on responder status. Citalopram nonresponders were the only group to decline on verbal learning and psychomotor speed. Citalopram responders showed significant improvement in visuospatial functioning, when compared with nonresponders in either condition, but their improvement was not greater than responders on placebo. Citalopram responders showed greater improvement on psychomotor speed than citalopram nonresponders, but their improvement was not greater than placebo responders or nonresponders. CONCLUSIONS: Medication may have a deleterious effect on some aspects of cognition among patients aged 75 years and older who have not responded. This suggests that patients should not be maintained on a medication if they have not had an adequate response.
RCT Entities:
OBJECTIVE: Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed medications for geriatric depression. The association of late-life depression and cognitive impairment has been well documented. However, there have been few placebo-controlled trials examining the impact of SSRIs on cognitive functioning. DESIGN: Prepost neuropsychological (NP) data collected as part of an 8-week, double-blind, placebo-controlled trial of citalopram in depressedpatients aged 75 years and older were used to examine change in cognitive functioning. SETTING: University-affiliated outpatient psychiatry clinics. PARTICIPANTS: One hundred seventy-four community-dwelling men and women aged 75 years or older with nonpsychotic unipolar depression. MEASUREMENTS: NP assessments included mental status (Mini-Mental State Examination), psychomotor speed (Wechsler Adult Intelligence Scale-III Digit Symbol Subtest), reaction time (Choice Reaction Time), visual-spatial skill (Judgment of Line Orientation), executive functioning (Stroop Color/Word Test), and memory (Buschke Selective Reminding Test). RESULTS: Differences in the pattern of change by treatment group depended on responder status. Citalopram nonresponders were the only group to decline on verbal learning and psychomotor speed. Citalopram responders showed significant improvement in visuospatial functioning, when compared with nonresponders in either condition, but their improvement was not greater than responders on placebo. Citalopram responders showed greater improvement on psychomotor speed than citalopram nonresponders, but their improvement was not greater than placebo responders or nonresponders. CONCLUSIONS: Medication may have a deleterious effect on some aspects of cognition among patients aged 75 years and older who have not responded. This suggests that patients should not be maintained on a medication if they have not had an adequate response.
Authors: E Kramer-Ginsberg; B S Greenwald; K R Krishnan; B Christiansen; J Hu; M Ashtari; M Patel; S Pollack Journal: Am J Psychiatry Date: 1999-03 Impact factor: 18.112
Authors: M A Butters; J T Becker; R D Nebes; M D Zmuda; B H Mulsant; B G Pollock; C F Reynolds Journal: Am J Psychiatry Date: 2000-12 Impact factor: 18.112
Authors: Joseph S Goveas; Patricia E Hogan; Jane M Kotchen; Jordan W Smoller; Natalie L Denburg; JoAnn E Manson; Aruna Tummala; W Jerry Mysiw; Judith K Ockene; Nancy F Woods; Mark A Espeland; Sylvia Wassertheil-Smoller Journal: Int Psychogeriatr Date: 2012-02-03 Impact factor: 3.878
Authors: R Scott Mackin; J Craig Nelson; Kevin L Delucchi; Patrick J Raue; Derek D Satre; Dimitris N Kiosses; George S Alexopoulos; Patricia A Arean Journal: Am J Geriatr Psychiatry Date: 2014-02-26 Impact factor: 4.105
Authors: Jane S Saczynski; Allison B Rosen; Ryan J McCammon; Kara Zivin; Susan E Andrade; Kenneth M Langa; Sandeep Vijan; Paul A Pirraglia; Becky A Briesacher Journal: Am J Med Date: 2015-01-30 Impact factor: 4.965
Authors: Michelle E Culang-Reinlieb; Joel R Sneed; John G Keilp; Steven P Roose Journal: Int J Geriatr Psychiatry Date: 2011-09-15 Impact factor: 3.485
Authors: Sarah Shizuko Morimoto; Dora Kanellopoulos; Kevin J Manning; George S Alexopoulos Journal: Ann N Y Acad Sci Date: 2015-02-05 Impact factor: 5.691
Authors: Donovan T Maust; Frederic C Blow; Ilse R Wiechers; Helen C Kales; Steven C Marcus Journal: J Clin Psychiatry Date: 2017-04 Impact factor: 4.384
Authors: Deanna M Barch; Gina DʼAngelo; Carl Pieper; Consuelo H Wilkins; Kathleen Welsh-Bohmer; Warren Taylor; Keith S Garcia; Kenneth Gersing; P Murali Doraiswamy; Yvette I Sheline Journal: Am J Geriatr Psychiatry Date: 2012-08 Impact factor: 4.105
Authors: Anton P Porsteinsson; Lea T Drye; Bruce G Pollock; D P Devanand; Constantine Frangakis; Zahinoor Ismail; Christopher Marano; Curtis L Meinert; Jacobo E Mintzer; Cynthia A Munro; Gregory Pelton; Peter V Rabins; Paul B Rosenberg; Lon S Schneider; David M Shade; Daniel Weintraub; Jerome Yesavage; Constantine G Lyketsos Journal: JAMA Date: 2014-02-19 Impact factor: 56.272